Received Feb 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM / RA |
injection site soreness; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 70-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Concomitant products included Influenza vaccine. In SEP-2024, the patient received Arexvy (intramuscular, right deltoid). In SEP-2024, less than a day after receiving Arexvy, the patient experienced injection site pain (Verbatim: injection site soreness). The outcome of the injection site pain was not resolved. It was unknown if the reporter considered the injection site pain to be related to Arexvy. It was unknown if the company considered the injection site pain to be related to Arexvy. Additional Information: GSK Receipt Date: 13-JAN-2025 The patient self-reported this case. The patient received her Arexvy vaccine and her flu shot (manufacturer unknown) and her right deltoid became sore at the injection site on the day of the injection and had not yet resolved and it was still sore. The patient denied redness, swelling or warmth at the injection site and had not yet seen her doctor since her vaccination, and didn't plan to see him until April 2025
INFLUENZA VACCINE